Lead-212 PSV359 Therapy for Patients With Solid Tumors

Study Summary

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Conditions

Pancreatic Ductal Adenocarcinoma Gastric Cancer Esophageal Cancer Colorectal Cancer Ovarian Cancer Head and Neck Cancer Sarcoma Mesothelioma

Interventions / Drugs

[203Pb]Pb-PSV359 [212Pb]Pb-PSV359

View on ClinicalTrials.gov ↗

Sponsor

CATX

Perspective Therapeutics

Oncology

D38/100

Study Details

Enrollment112 participants

Primary Completion—

Lead SponsorPerspective Therapeutics

Data Retrieved2026-04-11 04:08:56.505154+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.